<DOC>
	<DOCNO>NCT02848131</DOCNO>
	<brief_summary>The study goal assess effect senescent cell clearance senescence burden , physical ability frailty , adipose tissue-derived mesenchymal stem cell ( MSC ) functionality patient chronic kidney disease ( CKD ) .</brief_summary>
	<brief_title>Senescence Chronic Kidney Disease</brief_title>
	<detailed_description>The propose study examine cellular senescence effect senolytic therapy senescent cell burden , frailty , adipose-derived mesenchymal stem cell function individual diabetic chronic kidney disease .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Quercetin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Age 4080 year 2 . Chronic kidney disease estimate glomerular filtration rate ( eGFR ) 1545 ml/min/1.73m2 3 . Diabetes mellitus take diabetes medication 1 . Concomitant glomerulonephritis , 2 . Nephrotic syndrome , 3 . Solid organ transplantation , 4 . Autosomal dominant recessive polycystic kidney disease , 5 . Known renovascular disease , 6 . Pregnancy , 7 . Active immunosuppression therapy , 8 . Hemoglobin A1câ‰¥10 % screening , 9 . History active substance abuse ( include alcohol ) within past 2 year , 10 . Current alcohol abuse ( &gt; 3 alcoholic beverages/day &gt; 21 per week ) , 11 . Body weight &gt; 150 kg body mass index &gt; 50 12 . Human immunodeficiency virus infection 13 . Active hepatitis B C infection 14 . Tyrosine kinase inhibitor therapy 15 . Known hypersensitivity allergy dasatinib quercetin 16 . Inability give inform consent 17 . Uncontrolled systemic lupus erythematosus 18 . Uncontrolled pleural/pericardial effusion ascites 19 . New invasive cancer except nonmelanoma skin cancer 20 . Invasive fungal viral infection 21 . Inability tolerate oral medication 22 . Total bilirubin &gt; 2x upper limit normal 23 . Subjects take medication sensitive substrate substrate narrow therapeutic range CYP3A4 , CYP2C8 , CYP2C9 , CYP2D6 strong inhibitor inducer CYP3A4 ( e.g . cyclosporine , tacrolimus sirolimus ) . If antifungal absolutely necessary infectious disease perspective , allow level therapeutic . 24 . Subjects strong inhibitor CYP3A4 . 25 . Subjects therapeutic dos anticoagulant ( e.g . warfarin , heparin , low molecular weight heparin , factor Xa inhibitor , etc ) . 26 . Subjects antiplatelet agent ( e.g . full dose aspirin deem mandatory treatment , clopidogrel , etc. ) . Baby aspirin , necessary cardioprotection , allow . 27 . Subjects quinolone antibiotic therapy treatment prevention infection within 10 day 28 . Subjects take H2antagonists proton pump inhibitor unwilling discontinue therapy 1 week prior 2 week follow enrollment . 29 . Corrected QT interval ( QTc ) &gt; 450 msec</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>